

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEGS1646

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 DEC 01 ChemPort single article sales feature unavailable
NEWS 3 APR 03 CAS coverage of exemplified prophetic substances enhanced
NEWS 4 APR 07 STN is raising the limits on saved answers
NEWS 5 APR 24 CA/CAplus now has more comprehensive patent assignee information
NEWS 6 APR 26 USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS 7 APR 28 CAS patent authority coverage expanded
NEWS 8 APR 28 ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS 9 APR 28 Limits doubled for structure searching in CAS REGISTRY
NEWS 10 MAY 08 STN Express, Version 8.4, now available
NEWS 11 MAY 11 STN on the Web enhanced
NEWS 12 MAY 11 BEILSTEIN substance information now available on STN Easy
NEWS 13 MAY 14 DGENE, PCTGEN and USGENE enhanced with increased limits for exact sequence match searches and introduction of free HIT display format
NEWS 14 MAY 15 INPADOCDB and INPAFAMDB enhanced with Chinese legal status data
NEWS 15 MAY 28 CAS databases on STN enhanced with NANO super role in records back to 1992
NEWS 16 JUN 01 CAS REGISTRY Source of Registration (SR) searching enhanced on STN
NEWS 17 JUN 26 NUTRACEUT and PHARMAML no longer updated
NEWS 18 JUN 29 IMSCOPROFILE now reloaded monthly
NEWS 19 JUN 29 EPFULL adds Simultaneous Left and Right Truncation (SLART) to AB, MCLM, and TI fields
NEWS 20 JUL 09 PATDPAFULL adds Simultaneous Left and Right Truncation (SLART) to AB, CLM, MCLM, and TI fields

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial

products is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 09:34:26 ON 14 JUL 2009

=> File .Gerry2MBCE
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
0.22	0.22

FILE 'MEDLINE' ENTERED AT 09:34:48 ON 14 JUL 2009

FILE 'BIOSIS' ENTERED AT 09:34:48 ON 14 JUL 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 09:34:48 ON 14 JUL 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 09:34:48 ON 14 JUL 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

=> D Hist

(FILE 'HOME' ENTERED AT 09:34:26 ON 14 JUL 2009)

FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE' ENTERED AT 09:34:48 ON 14 JUL 2009

=> S ((Williams A/au) OR (Sereda T/au)) AND ((human growth factor) OR hGH)
L1 1 ((WILLIAMS A/AU) OR (SEREDA T/AU)) AND ((HUMAN GROWTH FACTOR)
OR HGH)

=> D Ibib abs L1

L1 ANSWER 1 OF 1 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2001420775 EMBASE

ACCESSION NUMBER: 2001R0775 RELEASE
TITLE: HIV patient acceptance of a needle-free device
(SeroJet®) for administering recombinant human growth hormone in the treatment of HIV infection-associated cachexia

AUTHOR: Murray, F.T., Dr. (correspondence); Muurahainen, N.; Gertner, J.M.; Williams, A.; Santos, G.; Schepeler, M.; Richmond, G.; Finkelstein, J.; Nebiolo, L.; Gaccione, P.

CORPORATE SOURCE: Serono Laboratories, Inc., 100 Longwater Circle, Norwell, MA 02061 United States

SOURCE: Today's Therapeutic Trends, (2001) Vol. 19, No. 4, pp. 283-295

285-295.

ISSN: 0741-2320 CODEN: TTRBDH

COUNTRY: United States

COUNTRY: United States
DOCUMENT TYPE: Journal Article

DOCUMENT TYPE: Journal, Article
FILE SEGMENT: 027 Biophysics, Bioengineering and Medical
Instrumentation

Instrumentation Drug Literature Index

038 Adverse Reactions Title

039 Haverbe Reader
Pharmacy

006 Internal Medicine

LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20 Dec 2001
Last Updated on STN: 20 Dec 2001

AB A randomized, two-way crossover study of recombinant human growth hormone (somatropin; r-hGH [Serostim®]) 6 mg in 0.5 ml administered subcutaneously either by syringe or needle-free device (SeroJet®) injection was conducted in 78 HIV-positive adult male (65) and female (13) subjects with cachexia (wasting), to assess the acceptability of growth hormone administered using these two alternative methods of injection. In general, the study findings demonstrated similar results on the descriptive and comparative questionnaires for the needle with syringe and needle-free groups during the entire 14 days of growth hormone dosing. Descriptive questionnaires relating to hurt or pain, wetness, redness, and anxiety showed minimal responses in over 90% of patients, and in over 85% of patients with regard to stinging, with both the needle and syringe and needle-free administration. In addition, analysis of responses to comparative questions relating to ease of use, convenience, anxiety, pain and overall preference indicated no statistically significant differences between needle and needle-free administration. Male sex and a previous history of subcutaneous and intramuscular needle injections favored syringe with needle injection over needle-free administration, though not statistically significantly. In conclusion, needle-free administration of r-hGH with SeroJet® was well tolerated, as safe as conventional needle injection, and at least as acceptable to patients. The use of SeroJet® for Serostim® growth hormone administration may diminish the potential for accidental needlestick injury and/or transmission of blood-borne infection with no increase in adverse reactions, thus making this method of injection an advance for patients with communicable diseases who require treatment with injectable medications.

=> Log off H
SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 09:38:32 ON 14 JUL 2009

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEGS1646

PASSWORD:
* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'MEDLINE, BIOSIS, CAPLUS, EMBASE'
AT 09:42:32 ON 14 JUL 2009
FILE 'MEDLINE' ENTERED AT 09:42:32 ON 14 JUL 2009
FILE 'BIOSIS' ENTERED AT 09:42:32 ON 14 JUL 2009
Copyright (c) 2009 The Thomson Corporation
FILE 'CAPLUS' ENTERED AT 09:42:32 ON 14 JUL 2009
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'EMBASE' ENTERED AT 09:42:32 ON 14 JUL 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	24.11	24.33

=> S ((growth hormone) OR Somatotropin OR Somatropin OR GH) (S) (Formulation OR composition) (S) ((Polyethylene glycol) OR PEG)
L2 37 ((GROWTH HORMONE) OR SOMATOTROPIN OR SOMATROPIGN OR GH) (S) (FORMULATION OR COMPOSITION) (S) ((POLYETHYLENE GLYCOL) OR PEG)

=> DUP Rem L2

PROCESSING COMPLETED FOR L2

L3 34 DUP REM L2 (3 DUPLICATES REMOVED)
ANSWER '1' FROM FILE MEDLINE
ANSWERS '2-34' FROM FILE CAPLUS

=> D Ti L3 1-34

L3 ANSWER 1 OF 34 MEDLINE on STN DUPLICATE 1
TI Controlled release of growth hormone from thermosensitive triblock copolymer systems: In vitro and in vivo evaluation.

L3 ANSWER 2 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Pharmaceutical compositions containing human growth hormone

L3 ANSWER 3 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Human growth hormone formulations

L3 ANSWER 4 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Streptoverticillium transglutaminase variants with improved specificity towards human growth hormone, and use for the preparation of pharmaceutical compositions

L3 ANSWER 5 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Ceramic implant composition comprising bioactive glass particles in glycerol/polyethylene glycol carrier aqueous solution, for filling bone defects

L3 ANSWER 6 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Sustained-release fine particle compositions and their manufacture

L3 ANSWER 7 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Pharmaceutical compositions containing the conjugates of polyethylene glycol with oligopeptide and proteins

L3 ANSWER 8 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Human growth hormone patch formulations

L3 ANSWER 9 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Liquid formulation comprising human growth hormone whose deamidation and agglutination are minimized

L3 ANSWER 10 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Stable growth hormone liquid formulation

L3 ANSWER 11 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI A pharmaceutical composition comprising a recombinant nonglycosylated immunoglobulin Fc region conjugated to a therapeutic protein as a drug carrier

L3 ANSWER 12 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI A pharmaceutical composition comprising aglycosylated IgG Fc fragment as a drug carrier, and method for the preparation thereof

L3 ANSWER 13 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Long-acting modified proteins used in sustained release formulations for reduced clearance

- L3 ANSWER 14 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Liquid human growth hormone formulation containing polyethylene glycol
- L3 ANSWER 15 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Compositions and methods for enhanced mucosal delivery of growth hormone
- L3 ANSWER 16 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Human growth hormone conjugated with biocompatible polymer
- L3 ANSWER 17 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Composition for stabilized liquid formulation of human growth hormone which minimizes deamidation, polymer formation and oxidative dissociation of human growth hormone(hGH)
- L3 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Novel Long-Acting Crystal Formulation of Human Growth Hormone
- L3 ANSWER 19 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Methods and compositions for the preparation of human growth hormone (hCG) glycosylation mutants with reduced immunogenicity, and therapeutic uses thereof
- L3 ANSWER 20 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Human growth hormone crystals and methods for preparing them
- L3 ANSWER 21 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Biodegradable pharmaceutical composition enabling sustained release of human growth hormone and microsphere thereof
- L3 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Sustained release formulations for growth hormone secretagogues
- L3 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Optimization of the molecular properties and formulation of proteins delivered by inhalation by pegylation or glycosylation
- L3 ANSWER 24 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI A somatotropin composition with improved syringeability
- L3 ANSWER 25 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Sustained releasing composition comprising somatotropin
- L3 ANSWER 26 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Wound healing compositions containing cell culture medium and growth hormones
- L3 ANSWER 27 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Sustained-release protein formulations with PEG and triacetin
- L3 ANSWER 28 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Implantable composition for the controlled release of somatotropin
- L3 ANSWER 29 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Oral compositions of proteinaceous medicaments
- L3 ANSWER 30 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Injection formulations containing therapeutic peptides and hormones
- L3 ANSWER 31 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Improved high-impact, antistatic, rubber-modified styrene polymer

compositions

- L3 ANSWER 32 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Toilet-cleaning compositions containing polyethylene glycols and ethylene oxide-propylene oxide copolymers
- L3 ANSWER 33 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Water-based ink compositions for ball point pens
- L3 ANSWER 34 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
TI Long-acting somatostatin composition

=> D ibib abs L3 1-34

L3 ANSWER 1 OF 34 MEDLINE on STN DUPLICATE 1
ACCESSION NUMBER: 2008138257 MEDLINE
DOCUMENT NUMBER: PubMed ID: 18036752
TITLE: Controlled release of growth hormone from thermosensitive triblock copolymer systems: In vitro and in vivo evaluation.
AUTHOR: Chen Sibao; Singh Jagdish
CORPORATE SOURCE: Department of Pharmaceutical Sciences, College of Pharmacy, Nursing, and Allied Sciences, North Dakota State University, Fargo, ND 58105, USA.
CONTRACT NUMBER: HD4137 (United States NICHD NIH HHS)
SOURCE: International journal of pharmaceutics, (2008 Mar 20) Vol. 352, No. 1-2, pp. 58-65. Electronic Publication:
2007-10-22.
Journal code: 7804127. ISSN: 0378-5173.
PUB. COUNTRY: Netherlands
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, N.I.H., EXTRAMURAL)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200807
ENTRY DATE: Entered STN: 27 Feb 2008
Last Updated on STN: 23 Jul 2008
Entered Medline: 22 Jul 2008

AB The purpose of this study was to design injectable controlled release polymer formulations for growth hormone using triblock copolymer PLGA-PEG-PLGA (MW 1400-1000-1400). Porcine growth hormone (pGH) formulations were prepared by adding pGH into 30% (w/v) aqueous solution of triblock copolymer. pGH concentrations in the released samples were determined using a standard MicroBCA method. In vitro release studies demonstrated that there were no initial burst of pGH from both formulations containing a low dose (0.12%, w/v) and a high dose (0.42%, w/v) of pGH. In vivo absorption study of pGH in rabbits showed that constant serum levels of exogenous pGH (3-7 ng/mL from high dose and 2-4 ng/mL from low dose) were detected for nearly 4 weeks from delivery systems upon single subcutaneous injection. The absolute bioavailability of pGH enhanced from the thermosensitive polymer-based systems, which was approximately 5-15-fold those of subcutaneous aqueous solution. MTT assay and light microscopy were used to investigate the in vitro and in vivo biocompatibility of thermosensitive polymer delivery systems, respectively. Both in vitro and in vivo results support the biocompatible nature of these polymer delivery systems. Thus, the triblock copolymer used in this study was able to control the release of incorporated pGH in vitro and in vivo for longer duration and the delivery system was biocompatible.

L3 ANSWER 2 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:1127506 CAPLUS
 DOCUMENT NUMBER: 149:340028
 TITLE: Pharmaceutical compositions containing human growth hormone
 INVENTOR(S): Patel, Ashish Binpin; Azria, Moise; Li, Shoufeng
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.
 SOURCE: PCT Int. Appl., 21pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008112836	A2	20080918	WO 2008-US56757	20080313
WO 2008112836	A3	20081204		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRIORITY APPLN. INFO.: US 2007-894961P P 20070315
 AB The invention pertains to a suppository that enables the successful delivery of human growth hormone (hGH), to a subject via administration of the suppository and provides pharmaceutical compns. which are suppositories comprising a human growth hormone as the active ingredient together with the delivery agent 5-CNAC, where the pharmaceutical provides bioavailability, e.g. satisfactory or optimal rectal bioavailability for the human growth hormone active ingredient. Using a 96% PEG-1000, 4% PEG-4000, and a cocoa butter base, hGH was absorbed at therapeutic levels by using 5-CNAC in Rhesus monkeys.

L3 ANSWER 3 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:771340 CAPLUS
 DOCUMENT NUMBER: 149:87638
 TITLE: Human growth hormone formulations
 INVENTOR(S): Chung, Wen-Li; Bush, Lawrence; Pechenov, Sergey; Basu, Sujit K.
 PATENT ASSIGNEE(S): Altus Pharmaceuticals Inc., USA
 SOURCE: PCT Int. Appl., 145pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008076819	A2	20080626	WO 2007-US87417	20071213
WO 2008076819	A3	20090326		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,			

KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
 PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2006-870605P P 20061218

AB Formulations containing complexed human growth hormone crystals are described.
 Also described are needleless injection systems for crystalline proteins.
 Thus, a human growth hormone formulation
 comprised human growth hormone derivative crystals at 5-50
 mg/mL, phosphate buffer at pH of 6.1-6.8, sodium chloride or sodium
 acetate at 60-200 mM, 2.5-20% PEG, with the formulation
 being disposed in a siliconized prefilled syringe with no more than 10 mm
 head space; and a volume of 0.2-1.0 mL.

L3 ANSWER 4 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:223214 CAPLUS

DOCUMENT NUMBER: 148:278902

TITLE: Streptoverticillium transglutaminase variants with
 improved specificity towards human growth hormone, and

use for the preparation of pharmaceutical compositions
 Hu, Zhixiang; Zhao, Xin; Wang, Jianhua; Chang,
 Chih-Chuan; Noerskov-Lauritsen, Leif

PATENT ASSIGNEE(S): Novo Nordisk Health Care A.-G., Switz.

SOURCE: PCT Int. Appl., 64pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008020075	A1	20080221	WO 2007-EP58571	20070817
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
WO 2007020290	A1	20070222	WO 2006-EP65439	20060818
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

	KG, KZ, MD, RU, TJ, TM			
EP 2054436	A1	20090506	EP 2007-802683	20070817
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
WO 2008102007	A1	20080828	WO 2008-EP52190	20080222
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
WO 2008102008	A1	20080828	WO 2008-EP52194	20080222
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			WO 2006-EP65439	A 20060818
			EP 2007-102885	A 20070222
			EP 2007-102886	A 20070222
			EP 2005-107599	A 20050818
			WO 2007-EP58571	W 20070817

AB Variants of transglutaminase from *Streptoverticillium ladakanum* and *S. mobaraense*, which variants have improved selectivity for Gln-141 of human growth hormone (hGH) are provided. The transglutaminase variants with improved selectivity are used for conjugating hGH at Gln-141. The conjugated hGH is used for the preparation of PEGylated hGH for the use in pharmaceutical compns. for treating hGH-associated diseases.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN				
ACCESSION NUMBER: 2008:1129938 CAPLUS				
DOCUMENT NUMBER: 149:363068				
TITLE: Ceramic implant composition comprising bioactive glass particles in glycerol/polyethylene glycol carrier aqueous solution, for filling bone defects				
INVENTOR(S): Depaula, Carl Alexander				
PATENT ASSIGNEE(S): USA				
SOURCE: U.S. Pat. Appl. Publ., 9pp.				
DOCUMENT TYPE: Patent				
LANGUAGE: English				
FAMILY ACC. NUM. COUNT: 1				
PATENT INFORMATION:				

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

US 20080226688	A1	20080918	US 2007-724255	20070315
CA 2582551	A1	20080915	CA 2007-2582551	20070322
CN 101264340	A	20080917	CN 2007-10185030	20071106
PRIORITY APPLN. INFO.:			US 2007-724255	A 20070315

AB The invention is directed toward a sterile formable implant composition for application to a bone defect site comprising bioactive glass particles in an aqueous carrier solution, the bioactive glass particles being added to a viscous carrier at a concentration ranging from about 68% to about 76% (weight/weight),

the carrier comprising a mixture of glycerol and polyethylene glycol ranging from 24% to 32% (weight/weight) with the ratio of glycerol to polyethylene glycol ranging from about 45:55 to about 65:35. Thus, putty composition was formulated by mixing 6.5 g of bioactive glass particles (90 μm to 710 μm) (62 wt%) and 1.5 g of bioactive glass powder (32 μm to 90 μm) (14 wt%) with 2.4 g of carrier (24 wt%) made up of glycerol and PEG having a mol. weight of 2000 in a ratio of 60:40; the composition had a total glass percentage (76 wt%) forming a putty which was acceptable.

L3 ANSWER 6 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:548987 CAPLUS
 DOCUMENT NUMBER: 148:546092
 TITLE: Sustained-release fine particle compositions and their manufacture
 INVENTOR(S): Nagao, Takeshi; Miyamoto, Yoko; Niimi, Jun
 PATENT ASSIGNEE(S): Galen Search Laboratories, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 14pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2008106024	A	20080508	JP 2006-292936	20061027
PRIORITY APPLN. INFO.:			JP 2006-292936	20061027


AB Title compns. comprise are manufactured by mixing aqueous solns. of water-soluble

divalent metal compds. with protein pharmaceuticals adsorbed into porous hydroxyapatite derivative fine particles at absorption rate 40-80%, freeze-drying, aqueous solns. or suspensions of hydrophilic biodegradable polymers, then freeze- or vacuum-drying. Thus, Zn-substituted hydroxyapatite was mixed with aqueous human growth hormone (hGH) and buffer solution, centrifuged, supernatant removed, mixed with aqueous ZnCl₂, freeze-dried, mixed with aqueous acetone solution of poly(lactic acid)-polyethylene glycol-poly(lactic acid) block copolymer, and freeze-dried to give fine powder composition, which released 5.2% hGH to phosphate buffer physiol. saline in 5 h.

L3 ANSWER 7 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:538036 CAPLUS
 DOCUMENT NUMBER: 148:592937
 TITLE: Pharmaceutical compositions containing the conjugates of polyethylene glycol with oligopeptide and proteins
 INVENTOR(S): Zhao, Xuan; Gu, Qiang
 PATENT ASSIGNEE(S): Beijing Jiankai Technology Co., Ltd., Peop. Rep. China
 SOURCE: Faming Zhanli Shengqing Gongkai Shuomingshu, 23pp.
 CODEN: CNXXEV
 DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101168594	A	20080430	CN 2006-10150011	20061024
WO 2008052428	A1	20080508	WO 2007-CN3030	20071024
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			CN 2006-10150011	A 20061024
GI				



AB The title compound formed from polyethylene glycol and oligopeptide/protein can be expressed as formula I, $(\text{PEG}_i - X_i)^j - A - (F_p)^q$, in which $i = 1-j$ integer; $j = >= 2$ integer; and X_i can be the same or not connecting group; A comes from oligopeptide containing 2-20 amino acids, wherein at least two amino acids are different; and F_p is the active group selected from hydroxyl, acryl chloride, carboxyl, ester, acyl, hydrazide, maleimide, and pyridine disulfide; P is 1-q integer. The obtained compound can bond with proteins or polypeptides of macromol. or natural pharmaceutical active components via F_p to improve in-vivo physiol. function of pharmaceutical mols. or maintain pharmaceutical concentration and supply sustained-release function.

L3 ANSWER 8 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2007:538922 CAPLUS
 DOCUMENT NUMBER: 146:487803
 TITLE: Human growth hormone patch formulations
 INVENTOR(S): Sacks, Hagit; Stern, Meir
 PATENT ASSIGNEE(S): Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.; Transpharma Medical Ltd.
 SOURCE: PCT Int. Appl., 22pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007056105	A2	20070518	WO 2006-US42894	20061102
WO 2007056105	A3	20070705		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,				

RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
 TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
 CA 2634181 A1 20070518 CA 2006-2634181 20061102
 US 20070141132 A1 20070621 US 2006-592791 20061102
 EP 1948221 A2 20080730 EP 2006-836849 20061102
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
 JP 2009514869 T 20090409 JP 2008-539045 20061102
 US 20080226703 A1 20080918 US 2008-92239 20080430
 PRIORITY APPLN. INFO.:
 US 2005-733005P P 20051102
 US 2005-739288P P 20051122
 WO 2006-US42894 W 20061102

AB The invention encompasses a transdermal patch formulation comprising hGH, at least one sugar, one amino acid or polyol, and a buffer, wherein the buffer maintains the pH of the formulation in the range of 5 to 9 and the formulation does not contain both glycine and mannitol. For example, a transdermal patch formulation contained hGH, sucrose, and glycine in a phosphate buffer, wherein the concentration ratio of hGH, sucrose, and glycine is 0.85:0.8:0.26 to 0.85:1.20:0.40.

L3 ANSWER 9 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2007:703724 CAPLUS
 DOCUMENT NUMBER: 147:150948
 TITLE: Liquid formulation comprising human growth hormone whose deamidation and agglutination are minimized
 INVENTOR(S): Kim, Sun Hee; Chung, Yo Kyung; Chang, Jae Young; Lee, Sang Kil; Lee, Min Suk; Park, Seung Kook; Lee, Bong Yong
 PATENT ASSIGNEE(S): Daewoong Co., Ltd., S. Korea
 SOURCE: Repub. Korean Kongkae Taeho Kongbo, No pp. given
 CODEN: KRXXA7
 DOCUMENT TYPE: Patent
 LANGUAGE: Korean
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2006124449	A	20061205	KR 2005-46381	20050531
KR 769709	B1	20071023		
WO 2008004717	A1	20080110	WO 2006-KR2640	20060706
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 2049148	A1	20090422	EP 2006-769186	20060706
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,				

BA, HR, MK, RS

PRIORITY APPLN. INFO.:

KR 2005-46381

T0 20050531

WO 2006-KR2640

W 20060706

AB A liquid formulation containing human growth hormone is provided to enhance storage stability by minimizing deamidation and agglutination of human growth hormone. The liquid formulation contains: human growth hormone; L-lysine or L-arginine; and poly(oxyethylene) poly(oxypropylene) copolymer, polyethyleneglycol-15 polyoxystearate or polyethyleneglycol-35 castor oil, wherein the amount of human growth hormone is 2.5-5.5 mg/mL, the amount of L-lysine or L-arginine is 0.02-0.5 w/v% per 1 mg of human growth hormone, and the amount of poly(oxyethylene) poly(oxypropylene) copolymer, polyethyleneglycol-15 polyoxystearate or polyethyleneglycol-35 castor oil is 0.1-0.5 w/v%; and the liquid formulation further contains at least one component selected from buffer solution, tonicity adjustment agent, preservative and analgesia.

L3 ANSWER 10 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:612122 CAPLUS

DOCUMENT NUMBER: 143:120561

TITLE: Stable growth hormone liquid formulation

INVENTOR(S): Badkar, Advait; Nema, Sandeep; Wadhwa, Manpreet

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063298	A1	20050714	WO 2004-IB4159	20041213
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2551510	A1	20050714	CA 2004-2551510	20041213
EP 1706150	A1	20061004	EP 2004-801396	20041213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
BR 2004018115	A	20070417	BR 2004-18115	20041213
JP 2007516274	T	20070621	JP 2006-546366	20041213
MX 2006006535	A	20060731	MX 2006-6535	20060608
US 20080125356	A1	20080529	US 2007-583923	20070514
PRIORITY APPLN. INFO.:			US 2003-531843P	P 20031223
			WO 2004-IB4159	W 20041213

AB The present invention is directed to stable liquid growth hormone formulations that remain stable after phys. agitation, and after exposure to one or more freeze-thaw events. Formulations of the present invention can be stored long term at a variety of temps., even frozen. In the present invention, a combination of buffer and stabilizing agents, including a non-ionic surfactant (e.g., polysorbate 20), a polymer stabilizer (e.g., polyethylene glycol), and other optional stabilizers combine to provide unexpected stability to aqueous formulations of a growth hormone (e.g., human

growth hormone).

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:451425 CAPLUS
DOCUMENT NUMBER: 143:13190
TITLE: A pharmaceutical composition comprising a recombinant nonglycosylated immunoglobulin Fc region conjugated to a therapeutic protein as a drug carrier
INVENTOR(S): Kim, Young Min; Song, Dae Hae; Jung, Sung Youb; Kim, Chang Hwan; Choi, In Young; Kwon, Se Chang; Lee, Gwan Sun
PATENT ASSIGNEE(S): Hanmi Pharm. Ind. Co., Ltd., S. Korea
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005047337	A1	20050526	WO 2004-KR2945	20041113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
KR 2005047030	A	20050519	KR 2004-92780	20041113
KR 2005047031	A	20050519	KR 2004-92781	20041113
KR 775343	B1	20071108		
KR 2005047032	A	20050519	KR 2004-92782	20041113
KR 2005047033	A	20050519	KR 2004-92783	20041113
CA 2512933	A1	20050526	CA 2004-2512933	20041113
AU 2004282985	A1	20050630	AU 2004-282985	20041113
AU 2004282985	B2	20080814		
AU 2004282984	A1	20050714	AU 2004-282984	20041113
BR 2004006606	A	20051206	BR 2004-6606	20041113
CN 1723219	A	20060118	CN 2004-80001770	20041113
CN 1723220	A	20060118	CN 2004-80001775	20041113
EP 1682584	A1	20060726	EP 2004-800092	20041113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
JP 2007537992	T	20071227	JP 2006-539399	20041113
RU 2352583	C2	20090420	RU 2005-120239	20041113
IN 2005DN02857	A	20070525	IN 2005-DN2857	20050627
MX 2005007211	A	20060210	MX 2005-7211	20050630
KR 2006054252	A	20060522	KR 2006-36697	20060424
US 20060275254	A1	20061207	US 2006-535231	20060724
PRIORITY APPLN. INFO.:			KR 2003-80299	A 20031113
			KR 2004-92780	A3 20041113
			WO 2004-KR2945	W 20041113

AB Disclosed is a novel use of an Ig Fc fragment, and more particularly, a pharmaceutical composition comprising an Ig Fc fragment as a carrier. Most preferable Ig Fc fragment is a human IgG4-derived nonglycosylated Fc

fragment produced by a prokaryote, preferably *E. coli*. Also demonstrated are preparation and pharmacokinetic anal. of α interferon (hIFN α -2b), human growth hormone, EPO, G-CSF and Fab' conjugated to various forms of Fc fragments through 3.4 kDa PEG. The pharmaceutical composition comprising an Ig Fc fragment as a carrier remarkably extends the serum half-life of a drug while maintaining the in vivo activity of the drug at relatively high levels. Also, when the drug is a polypeptide drug, the pharmaceutical composition has less risk of inducing immune responses compared to a fusion protein of the Ig Fc fragment and a target protein, and is thus useful for developing long-acting formulations of various polypeptide drugs.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 12 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:451422 CAPLUS
 DOCUMENT NUMBER: 143:13189
 TITLE: A pharmaceutical composition comprising aglycosylated IgG Fc fragment as a drug carrier, and method for the preparation thereof
 INVENTOR(S): Jung, Sung Youb; Kim, Jin Sun; Yang, Geun Hee; Kwon, Se Chang; Lee, Gwan Sun
 PATENT ASSIGNEE(S): Hanmi Pharm. Ind. Co., Ltd., S. Korea
 SOURCE: PCT Int. Appl., 131 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 7
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005047334	A1	20050526	WO 2004-KR2942	20041113
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
KR 2005047030	A	20050519	KR 2004-92780	20041113
KR 2005047031	A	20050519	KR 2004-92781	20041113
KR 775343	B1	20071108		
KR 2005047032	A	20050519	KR 2004-92782	20041113
KR 2005047033	A	20050519	KR 2004-92783	20041113
AU 2004282984	A1	20050714	AU 2004-282984	20041113
CN 1723219	A	20060118	CN 2004-80001770	20041113
CN 1723220	A	20060118	CN 2004-80001775	20041113
EP 1682581	A1	20060726	EP 2004-800089	20041113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
JP 2007531513	T	20071108	JP 2006-539396	20041113
KR 2006054252	A	20060522	KR 2006-36697	20060424
US 20070041967	A1	20070222	US 2006-535341	20060609
PRIORITY APPLN. INFO.:			KR 2003-80299	A 20031113
			KR 2004-92780	A3 20041113
			WO 2004-KR2942	W 20041113

AB Disclosed is an IgG Fc fragment useful as a drug carrier. Also, the

present invention discloses a recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment, comprising culturing the transformant. Preferably aglycosylated IgG2 Fc and IgG4 Fc fragments are used. Provided are sequences for IgG Fc fragments and Fc fragments-encoding genes. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug. Demonstrated is preparation of GH-,

G-CSF-PEG-Fc conjugates and INF α -PEG-deglycosylated Fc conjugates. Also demonstrated are changes in pharmacokinetics, cytotoxicity and activity of α interferon, human growth hormone and G-CSF.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:346886 CAPLUS

DOCUMENT NUMBER: 142:379425

TITLE: Long-acting modified proteins used in sustained release formulations for reduced clearance

INVENTOR(S): Jensen, Simon Bjerregaard; Iversen, Lars Fogh; Rischel, Christian; Reslow, Mats

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.

SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005034988	A1	20050421	WO 2004-DK684	20041008
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1677819	A1	20060712	EP 2004-762903	20041008
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007508250	T	20070405	JP 2006-529652	20041008
US 20060257479	A1	20061116	US 2006-395770	20060331
PRIORITY APPLN. INFO.:			DK 2003-1496 US 2003-510892P WO 2004-DK684	A 20031010 P 20031014 W 20041008

AB Sustained release formulations comprising mols. modified so as to have a reduced clearance are provided. For example, human growth hormone conjugated with PEG used in sustained formulations containing hydrophobic polymers, such as PEG, and PGLA.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:283354 CAPLUS

DOCUMENT NUMBER: 142:322803
 TITLE: Liquid human growth hormone formulation containing polyethylene glycol
 INVENTOR(S): Williams, Ashley Martin; Sereda, Terrance Jimmy;
 Wiebe, Deanna June
 PATENT ASSIGNEE(S): Cangene Corporation, Can.
 SOURCE: PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005027960	A1	20050331	WO 2004-CA1698	20040927
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2540172	A1	20050331	CA 2004-2540172	20040927
EP 1663296	A1	20060607	EP 2004-761854	20040927
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2007506683	T	20070322	JP 2006-527240	20040927
US 20090029911	A1	20090129	US 2007-573571	20070322
PRIORITY APPLN. INFO.:			US 2003-505432P	P 20030925
			WO 2004-CA1698	W 20040927

AB A stable pharmaceutically acceptable aqueous formulation contains human growth hormone, a buffer, polyethylene glycol, a tonicifier such as a sugar alc., and optionally, an antimicrobial agent and optionally, a chelating agent. Also disclosed are associated means and methods for preparing, storing and using such formulations. thus, a formulation containing PEG, buffer, tonicifying agent, protected the hGH against both phys. and chemical degradation during long-term storage.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:55083 CAPLUS
 DOCUMENT NUMBER: 142:141264
 TITLE: Compositions and methods for enhanced mucosal delivery of growth hormone
 INVENTOR(S): Quay, Steven C.; De Meireles, Jorge C.; Gupta, Malini;
 Vangala, Shyam
 PATENT ASSIGNEE(S): Nastech Pharmaceutical Company Inc., USA
 SOURCE: PCT Int. Appl., 108 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005004895	A2	20050120	WO 2004-US17632	20040601
WO 2005004895	A3	20050915		
W: AE, AG, AL, AM, AT, AU, AZ, CN, CO, CR, CU, CZ, DE, DK, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PG, PH, PL, RO, RU, SC, SD, SE, SG, SK, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	BA, BB, BG, BR, BW, BY, BZ, CA, CH, EC, EE, EG, ES, FI, GB, GD, KG, KP, KR, KZ, LC, NA, NI, MW, MX, MZ, NA, NI, SG, SK, SL, SY, UG, ZM, ZW, AM, BE, BG, CH, CY, CZ, DE, DK, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2528465	A1	20050120	CA 2004-2528465	20040601
US 20050031549	A1	20050210	US 2004-862141	20040601
EP 1643970	A2	20060412	EP 2004-754279	20040601
R: AT, BE, CH, DE, DK, ES, FR, IE, SI, LT, LV, FI, RO, MK,	GB, GR, IT, LI, LU, NL, SE, MC, PT, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2007500243	T	20070111	JP 2006-533559	20040601
MX 2005013340	A	20060309	MX 2005-13340	20051208
PRIORITY APPLN. INFO.:			US 2003-477403P	P 20030609
			WO 2004-US17632	W 20040601

AB Pharmaceutical formulations are described comprising at least one growth hormone and one or more intranasal delivery-enhancing agents for enhanced nasal mucosal delivery of the growth hormone. In one aspect, the intranasal delivery formulations and methods provide enhanced delivery of growth hormone to the blood plasma, for example, by yielding a peak concentration

(Cmax) of the growth hormone in an hepatic portal vein or a blood plasma of the subject that is 20% or greater compared to a peak concentration of the growth hormone in the hepatic portal vein or the blood plasma of the subject following administration to the subject of a same concentration or dose of the growth hormone to the subject by s.c. injection. Exemplary formulations and methods within the invention utilize human growth hormone as the hormone. A composition contained growth hormone, sucrose, phosphate, arginine-HCl, di-Na EDTA, and water.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 16 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:1334140 CAPLUS
 DOCUMENT NUMBER: 144:74823
 TITLE: Human growth hormone conjugated with biocompatible polymer
 INVENTOR(S): Park, Myung-Ok; Jacobs, John W.
 PATENT ASSIGNEE(S): Phage Biotechnology Corporation, USA
 SOURCE: U.S. Pat. Appl. Publ., 48 pp., Cont.-in-part of U.S. Ser. No. 947,513.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050281778	A1	20051222	US 2005-187522	20050722
KR 2004086521	A	20041011	KR 2004-7983	20040206
WO 2004084948	A1	20041007	WO 2004-KR701	20040327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
US 20050059129	A1 20050317	US 2004-947513	20040922
US 20060134736	A1 20060622	US 2005-314926	20051220
AU 2005335186	A1 20070215	AU 2005-335186	20051220
CA 2616187	A1 20070215	CA 2005-2616187	20051220
WO 2007018583	A2 20070215	WO 2005-US46791	20051220
WO 2007018583	A3 20070531		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 1915179	A2 20080430	EP 2005-855362	20051220
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
JP 2009502779	T 20090129	JP 2008-522759	20051220
KR 2008041661	A 20080513	KR 2008-704205	20080221
KR 2003-19734 A 20030328 KR 2004-7983 A 20040206 WO 2004-KR701 A2 20040327 US 2004-947513 A2 20040922 US 2005-187522 A2 20050722 WO 2005-US46791 W 20051220			

PRIORITY APPLN. INFO.:

AB The present invention relates to conjugates of biocompatible polymers and biol. active proteins, such as human growth hormone (hGH), particularly PEG-hGH, where the activated biocompatible polymer is conjugated to a carboxyl group of hGH at a molar ratio of 1:1, methods of preparation, and related pharmaceutical compns. The PEG-hGH conjugates have up to 20% of the activity of the native hGH while the in vivo half life is increased 10 fold. The PEG-hGH conjugates may be used therapeutically to treat growth retardation or growth failure, especially short stature in children, and conditions related to aging. Thus, the PEG-hGH conjugate was prepared by reacting hGH with PEG derivs. activated with EDAC. The reaction was carried out for 1 h at 25° using either PEG 20,000 or PEG 30,000. MonoPEG-hGH and diPEG-hGH were obtained and purified by HPLC using a size-exclusion column. Mono- and diPEG-hGH retained 15±5% and 8±2% of biol. activity, resp., as compared to native hGH. However, the PEG-hGH was cleared much slower than native hGH in rats. Thus, the PEG-hGH samples of this study can provide a new sustained released drug of hGH.

L3 ANSWER 17 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:877511 CAPLUS

DOCUMENT NUMBER: 145:278290

TITLE: Composition for stabilized liquid formulation of human growth hormone which minimizes deamidation, polymer

formation and oxidative dissociation of human growth
 hormone(hGH)
 INVENTOR(S): Jung, Sung Youb; Kim, Young Min; Kwon, Se Chang; Lee,
 Gwan Sun; Yang, Geun Hee
 PATENT ASSIGNEE(S): Hanmi Pharm. Ind. Co., Ltd., S. Korea
 SOURCE: Repub. Korean Kongkae Taeho Kongbo, No pp. given
 CODEN: KRXXA7
 DOCUMENT TYPE: Patent
 LANGUAGE: Korean
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2005023875	A	20050310	KR 2003-61434	20030903
PRIORITY APPLN. INFO.:			KR 2003-61434	20030903

AB A composition for stabilized liquid formulation of human growth hormone is provided which minimizes deamidation, polymer formation and oxidative dissociation of human growth hormone(hGH). The stability of the liquid formulation was improved. The composition for stabilized liquid formulation of human growth hormone comprises 1 to 10 mg/mL human growth hormone(hGH), 5 to 100 mM buffering agent, 0.001 to 20 mg/mL polyethylene glycol and 5 to 100 mg/mL tonicity adjustment agent, wherein the human growth hormone is recombinant methionyl human growth hormone or recombinant natural human growth hormone; the buffering agent is sodium citrate; the tonicity adjustment agent comprises sodium chloride, mannitol and a mixture thereof; and the composition has pH 5.5 to 6.5.

L3 ANSWER 18 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:901684 CAPLUS
 DOCUMENT NUMBER: 144:27270
 TITLE: Novel Long-Acting Crystal Formulation of Human Growth Hormone
 AUTHOR(S): Govardhan, Chandrika; Khalaf, Nazer; Jung, Chu W.;
 Simeone, Ben; Higbie, Amy; Qu, Susan; Chemmalil, Letha; Pechenov, Sergey; Basu, Sujit K.; Margolin, Alexey L.
 CORPORATE SOURCE: Altus Pharmaceuticals Inc., Cambridge, MA, 02139, USA
 SOURCE: Pharmaceutical Research (2005), 22(9), 1461-1470
 CODEN: PHREEB; ISSN: 0724-8741
 PUBLISHER: Springer Science+Business Media, Inc.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The aim of the study is to solve a significant challenge of extending the half-life of therapeutic proteins using crystalline biopharmaceuticals and without redesigning the mols. Crystals of recombinant human growth hormone were coated with a monomol. layer of pos. charged poly(arginine). The pharmacokinetics and pharmacodynamics of this poly(arginine)-coated human growth hormone crystalline formulation were determined in hypophysectomized rats and monkeys. Here the authors have demonstrated for the first time that crystals of human growth hormone coated with pos. charged poly(arginine) allowed for in vivo pharmacokinetic release profiles of over several days in animal models. The efficacy of this crystalline formulation injected s.c. once a week was found to be equivalent to 7 daily soluble injections in the standard weight gain assay using the hypophysectomized rat model and in measurement of serum insulin-like growth factor in monkeys. The nonviscous nature of the suspension facilitated easy administration through a fine, 30-gauge needle and should provide for improved patient

convenience and compliance. The approach described here offers an exciting possibility of being broadly applicable to other therapeutic proteins.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 19 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:1033550 CAPLUS
DOCUMENT NUMBER: 142:33306
TITLE: Methods and compositions for the preparation of human growth hormone (hCG) glycosylation mutants with reduced immunogenicity, and therapeutic uses thereof
INVENTOR(S): Clausen, Henrik
PATENT ASSIGNEE(S): Neose Technologies, Inc., USA; Defrees, Shawn
SOURCE: PCT Int. Appl., 136 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103275	A2	20041202	WO 2004-US14254	20040507
WO 2004103275	A3	20070518		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA				
AU 2004240553	A1	20041202	AU 2004-240553	20040507
CA 2524936	A1	20041202	CA 2004-2524936	20040507
EP 1624847	A2	20060215	EP 2004-751591	20040507
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004010164	A	20060516	BR 2004-10164	20040507
JP 2007523630	T	20070823	JP 2006-532844	20040507
CN 101080238	A	20071128	CN 2004-80016847	20040507
ZA 2005009864	A	20080227	ZA 2005-9864	20040507
MX 2005011832	A	20060217	MX 2005-11832	20051103
KR 2006030023	A	20060407	KR 2005-721304	20051109
IN 2005KN02351	A	20060825	IN 2005-KN2351	20051123
US 20080102083	A1	20080501	US 2007-556094	20070416
PRIORITY APPLN. INFO.:			US 2003-469114P	P 20030509
			US 2003-494751P	P 20030813
			US 2003-495076P	P 20030814
			US 2004-535290P	P 20040108
			WO 2004-US14254	W 20040507

AB The present invention relates to mutants of human growth hormone, which contain newly introduced N-linked or O-linked glycosylation site(s), such that these recombinantly produced polypeptides have glycosylation patterns distinctly different from that of the naturally occurring human growth hormone. The polynucleotide coding sequences for the mutants, expression cassettes comprising the coding sequences, cells expressing the mutants, and methods for producing the mutants are also disclosed. Further disclosed are pharmaceutical compns. comprising the mutants and method for

using the mutants.

L3 ANSWER 20 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:589380 CAPLUS
DOCUMENT NUMBER: 141:128854
TITLE: Human growth hormone crystals and methods for preparing them
INVENTOR(S): Govardhan, Chandrika; Khalaf, Nazer; Simeone, Benjamin Paul
PATENT ASSIGNEE(S): Altus Biologics Inc., USA
SOURCE: PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004060310	A2	20040722	WO 2003-US41545	20031231
WO 2004060310	A3	20041209		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2512052	A1	20040722	CA 2003-2512052	20031231
AU 2003303646	A1	20040729	AU 2003-303646	20031231
US 20040209804	A1	20041021	US 2003-749962	20031231
EP 1581251	A2	20051005	EP 2003-808602	20031231
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017888	A	20051206	BR 2003-17888	20031231
CN 1744914	A	20060308	CN 2003-80109408	20031231
JP 2006512416	T	20060413	JP 2005-508635	20031231
ZA 2005005305	A	20070725	ZA 2005-5305	20031231
RU 2357750	C2	20090610	RU 2005-124280	20031231
IN 2005KN01264	A	20070309	IN 2005-KN1264	20050629
MX 2005007181	A	20060407	MX 2005-7181	20050630
IN 2008KN02347	A	20090123	IN 2008-KN2347	20080611
PRIORITY APPLN. INFO.:				
		US 2002-437519P	P	20021231
		US 2003-517042P	P	20031103
		WO 2003-US41545	W	20031231
		IN 2005-KN1264	A3	20050629

AB The present invention relates to stable, extended release crystals of human growth hormone (hGH) or a human growth hormone derivative and compns. or formulations comprising such crystals. The invention further provides methods for producing those crystals and compns. The invention further provides methods for treatment of an individual having disorders associated with human growth hormone deficiency or which are ameliorated by treatment with human growth hormone using those crystals and compns. or formulations. For example, crystallization of hGH with calcium acetate, PEG-6000 and protamine sulfate was carried out. Com. available hGH was purified and concentrated, and deionized water was added to the concentrated hGH solution to yield a final protein concentration of 15 mg/mL. Tris-HCl (1 M, pH 8.6) was added to a

final concentration of 100 mM. To this solution, protamine sulfate (1 mg/mL) and 6%

PEG-6000 (volume/volume) was added. Crystals of hGH were grown by adding calcium acetate (1 M) to the solution so that a final concentration of 85 mM calcium

acetate was obtained. The solution was then incubated for 16 h at 37°. Needle-like crystals obtained were found to be less than 25 µm in length with a crystallization yield of > 70%.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 21 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:955600 CAPLUS

DOCUMENT NUMBER: 142:204674

TITLE: Biodegradable pharmaceutical composition enabling sustained release of human growth hormone and microsphere thereof

INVENTOR(S): Cho, Yeong U.; Kim, Hong Gi; Kim, Won Bae; Lee, Geon Il; Lee, Seong Hui; Park, Tae Gwan; Park, Yong Man

PATENT ASSIGNEE(S): Dong-A Pharm. Co., Ltd., S. Korea; Korea Advanced Institute of Science and Technology

SOURCE: Repub. Korean Kongkae Taeho Kongbo, No pp. given
CODEN: KRXXA7

DOCUMENT TYPE: Patent

LANGUAGE: Korean

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
KR 2003006455	A	20030123	KR 2001-42196	20010713
KR 838219	B1	20080613		

PRIORITY APPLN. INFO.: KR 2001-42196 20010713

AB A microsphere containing a drug obtained by adding polyethylene glycol as a protein stabilizer in an appropriate ratio and then including human growth hormone into the microsphere is provided which enables the human growth hormone to continuously release from the microsphere for two weeks even in vivo as well as in vitro. The microspherical composition contains human growth hormone, polyethylene glycol or a derivative thereof as a protein stabilizer, a biodegradable polyester polymer as a polymer carrier, a surfactant and an emulsifier, wherein the human growth hormone and polyethylene glycol or a mixture thereof are dispersed in a droplet of the surfactant to form a first emulsion. The first emulsion is dispersed in the droplet of the emulsion.

L3 ANSWER 22 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2002:171688 CAPLUS

DOCUMENT NUMBER: 136:221723

TITLE: Sustained release formulations for growth hormone secretagogues

INVENTOR(S): Am Ende, Mary Tanya; Curatolo, William John; Herbig, Scott Max

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 137 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----	-----	-----	-----	
WO 2002017918	A2	20020307	WO 2001-IB1429	20010808
WO 2002017918	A3	20020725		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2420535	A1	20020307	CA 2001-2420535	20010808
AU 2001076608	A	20020313	AU 2001-76608	20010808
EP 1313473	A2	20030528	EP 2001-954267	20010808
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013626	A	20030617	BR 2001-13626	20010808
JP 2004507502	T	20040311	JP 2002-522891	20010808
US 20020137765	A1	20020926	US 2001-940097	20010827
US 6641840	B2	20031104		
MX 2003001771	A	20030604	MX 2003-1771	20030227
US 20040091530	A1	20040513	US 2003-611586	20030630
PRIORITY APPLN. INFO.:			US 2000-229074P	P 20000830
			WO 2001-IB1429	W 20010808
			US 2001-940097	A3 20010827

AB The present invention relates to formulations for administering a growth hormone secretagogue. More specifically, the present invention relates to sustained release formulations for administering a growth hormone secretagogue and formulations for administering a growth hormone secretagogue that provide for a part of the dose of the growth hormone secretagogue to be administered using an immediate release formulation and part of the dose of the growth hormone secretagogue to be administered using a sustained release formulation. Thus, a sustained release dosage form for oral administration contained 2-amino-N-[2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahyddropyrazolo[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxoethyl]isobutyramide L-tartrate 3.89, mannitol 34.00, fumaric acid 12.00, microcryst. cellulose 48.61, Mg stearate 1.50, cellulose acetate 11.90, and PEG 5.10 mg/tablet.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 23 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2002:869417 CAPLUS
 DOCUMENT NUMBER: 137:358174
 TITLE: Optimization of the molecular properties and formulation of proteins delivered by inhalation by pegylation or glycosylation
 INVENTOR(S): Gonda, Igor
 PATENT ASSIGNEE(S): Australia
 SOURCE: U.S. Pat. Appl. Publ., 6 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020168323	A1	20021114	US 2002-146549	20020513
CA 2445494	A1	20021121	CA 2002-2445494	20020513

WO 2002092147	A2	20021121	WO 2002-US15429	20020513
WO 2002092147	A3	20031127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002309848	A1	20021125	AU 2002-309848	20020513
EP 1392350	A2	20040303	EP 2002-736873	20020513
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004531550	T	20041014	JP 2002-589063	20020513
PRIORITY APPLN. INFO.:			US 2001-290292P	P 20010511
			WO 2002-US15429	W 20020513

AB Pegylation or glycosylation of therapeutic proteins enhances at least one of the solubility, stability and bioavailability, for delivery of an effective amount in an aerosol delivery to the lungs using a minimal number of puffs. E.g., the optimum pegylated derivative of recombinant human growth hormone is one that can be delivered in the min. number of breaths from a system such as AERx or Respimat.

L3 ANSWER 24 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2001:713164 CAPLUS
 DOCUMENT NUMBER: 135:262256
 TITLE: A somatotropin composition with improved syringeability
 INVENTOR(S): Kim, Nam Joong; Ryoo, Je Phil
 PATENT ASSIGNEE(S): Lg Chemical Ltd., S. Korea
 SOURCE: PCT Int. Appl., 36 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001070256	A1	20010927	WO 2000-KR1151	20001016
W: AU, BR, CA, MX, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
KR 2001089862	A	20011012	KR 2000-15091	20000324
CA 2374043	A1	20010927	CA 2000-2374043	20001016
BR 2000010947	A	20020312	BR 2000-10947	20001016
EP 1194160	A1	20020410	EP 2000-970270	20001016
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
AU 783240	B2	20051006	AU 2000-79671	20001016
EG 24204	A	20081020	EG 2001-295	20010324
MX 2001011719	A	20030910	MX 2001-11719	20011114
US 6733786	B1	20040511	US 2001-926590	20011121
PRIORITY APPLN. INFO.:			KR 2000-15091	A 20000324
			WO 2000-KR1151	W 20001016

AB An improved composition consists of somatotropin with activity in vivo, a lipid-soluble vitamin and at least 1 lubricant. This improves the poor syringeability under cold temps. of the conventional somatotropin formulation. Thus, bovine somatotropin solution was lyophilized and the

powder obtained was mixed with vitamin E acetate and benzyl alc. The above composition was filled in a polypropylene syringe and the sample was stored at ambient temperature and 4°.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 25 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:843144 CAPLUS
DOCUMENT NUMBER: 142:11539
TITLE: Sustained releasing composition comprising somatotropin
INVENTOR(S): Kim, Nam Joong; Joh, Heung Soo; Lee, Byung Kum
PATENT ASSIGNEE(S): LG Chemical Co., Ltd., S. Korea
SOURCE: Repub. Korea, No pp. given
CODEN: KRXXFC
DOCUMENT TYPE: Patent
LANGUAGE: Korean
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 143767	B1	19980715	KR 1991-24288	19911224
PRIORITY APPLN. INFO.: KR 1991-24288 19911224				
AB An implantable formula containing somatotropin is provided for sustained release of somatotropin that promotes animal's growth. A process for the preparation of sustained releasing formula containing somatotropin comprises of: mixing polyethylene glycol, the water-soluble polymer with somatotropin or liposome bovine somatotropin; adding some water and mixing; granulation; coating granulated compound by spraying hydroxy Pr cellulose dissolved in ethanol using spray gun; making tablet or pellet by tablet machine.				

L3 ANSWER 26 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:958515 CAPLUS
DOCUMENT NUMBER: 123:350357
ORIGINAL REFERENCE NO.: 123:62653a, 62656a
TITLE: Wound healing compositions containing cell culture medium and growth hormones
INVENTOR(S): Lindenbaum, Ella
PATENT ASSIGNEE(S): Life Medical Science, Inc., USA
SOURCE: U.S., 9 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5461030	A	19951024	US 1993-158808	19931129
US 5591709	A	19970107	US 1995-374944	19950118
PRIORITY APPLN. INFO.: IL 1991-97127 A 19910201 US 1991-752849 B1 19910830 US 1992-937486 B2 19920828 US 1993-25216 B2 19930302 US 1993-158808 A2 19931129				

AB The title formulations are useful for treating wounds by accelerating wound healing. These formulations comprise an effective amount of a serum free cellular nutrient medium in combination with an effective amount of at least one cellular growth stimulating compound, e.g. a natural anabolic hormone or transforming growth factor. Thus, 100 g of lyophilized powder

of MCDB 153 culture medium was reconstituted with water and supplemented with human growth hormone to final concentration of 0.5-2 ng/mL. In certain formulations insulin-transferrin was added to final concentration of 5 μ g/mL and collagen or gelatin at 4% concentration. The compns. were effective in treatment of pressure wound and skin ulcers.

REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 27 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1994:307496 CAPLUS
DOCUMENT NUMBER: 120:307496
ORIGINAL REFERENCE NO.: 120:53945a, 53948a
TITLE: Sustained-release protein formulations with PEG and triacetin
INVENTOR(S): Hageman, Michael J.
PATENT ASSIGNEE(S): Upjohn Co., USA
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9406452	A1	19940331	WO 1993-US7756	19930823
W: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9350186	A	19940412	AU 1993-50186	19930823
EP 661989	A1	19950712	EP 1993-920157	19930823
EP 661989	B1	19970806		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08501305	T	19960213	JP 1994-508083	19930823
JP 3756512	B2	20060315		
AT 156361	T	19970815	AT 1993-920157	19930823
ES 2107051	T3	19971116	ES 1993-920157	19930823
ZA 9306415	A	19950228	ZA 1993-6415	19930831
US 6011011	A	20000104	US 1995-407327	19950320
JP 2004285079	A	20041014	JP 2004-206098	20040713
PRIORITY APPLN. INFO.:				
		US 1992-947872	A2	19920921
		US 1992-963365	A2	19921020
		JP 1994-508083	A3	19930823
		WO 1993-US7756	W	19930823

AB Novel sustained-release injections of a protein or peptide, e.g. somatotropin (I) and growth hormone releasing factor, are prepared using triacetin or PEG. Thus, 25.01 g triacetin was mixed with 6.85 g bovine somatotropin to obtain a suspension containing 200mg I/mL. Cows were injected s.c. with 0.7mL of the suspension containing 150 mg I. The greatest quantity of I appeared in the serum 12-30 h post injection and remained elevated for .apprx.84 hs.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 28 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1994:638406 CAPLUS
DOCUMENT NUMBER: 121:238406
ORIGINAL REFERENCE NO.: 121:43325a, 43328a
TITLE: Implantable composition for the controlled release of somatotropin

INVENTOR(S): Kin, Nam Joong; Cho, Heung Soo; Sorig, Maeng Seok;
 Choi, Yun Jeong; Rhee, Byung Geon
 PATENT ASSIGNEE(S): Lucky Ltd., S. Korea
 SOURCE: Braz. Pedido PI, 33 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: Portuguese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BR 9305261	A	19940705	BR 1993-5261	19931228
AU 9352718	A	19940707	AU 1993-52718	19931223
AU 660119	B2	19950608		
CN 1093597	A	19941019	CN 1993-121466	19931228
US 5662917	A	19970902	US 1996-601275	19960322
PRIORITY APPLN. INFO.:			KR 1992-25904	A 19921228
			US 1993-171533	B1 19931222

AB The implantable composition claimed involves somatotropin, a biocompatible wax and a water-soluble polymer. Thus, 5 g lyophilized porcine somatotropin powder is mixed with 10 g polyethylene glycol (mol. weight 35,000) and 10 g paraffin wax, and the mixture is homogenized and formed into tablets measuring 7 mm in diameter and 6.2 mm in thickness. Each tablet contains 250 mg of the homogenized mixture. The product allows for prolonged release of somatotropin with few side effects.

L3 ANSWER 29 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:456164 CAPLUS
 DOCUMENT NUMBER: 119:56164
 ORIGINAL REFERENCE NO.: 119:9997a,10000a
 TITLE: Oral compositions of proteinaceous medicaments
 INVENTOR(S): Desai, Ashok J.
 PATENT ASSIGNEE(S): Applied Analytical Industries, Inc., USA
 SOURCE: U.S., 8 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5206219	A	19930427	US 1991-797221	19911125
PRIORITY APPLN. INFO.:			US 1991-797221	19911125

AB Proteinaceous medicaments (e.g. erythropoietin, insulin, calcitonin) are formulated in a medium containing a polyol pharmaceutical solvent combined as cosolvent with a lipid pharmaceutical solvent. The formulation is adapted for oral administration as a liquid as well as a filled hard or soft gelatin capsule. The preferred polyol solvent is PEG/propylene glycol, and the preferred lipid solvent is oleic acid. A capsule formulation contained (per capsule) insulin 140 IU, dimyristyl phosphatidylcholine 0.047, aprotinin 3.39, hydroxypropyl cellulose-LF 3.76, poly-oxy 40 stearate 3.76, PEG 400 139.8, propylene glycol 15.57, water/citrate buffer (pH adjustment) 8.75, cholesterol 31.2, Tween-80 17.56, egg yolk lecithin 63.1, glyceryl monooleate 27.9, d- α -tocopherol 19.6, and oleic acid 249.1 mg.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 30 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:656548 CAPLUS

DOCUMENT NUMBER: 119:256548
 ORIGINAL REFERENCE NO.: 119:45649a, 45652a
 TITLE: Injection formulations containing therapeutic peptides and hormones
 INVENTOR(S): Igari, Yasutaka; Yamada, Minoru; Ishiguro, Kyoko
 PATENT ASSIGNEE(S): Takeda Chemical Industries Ltd, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 16 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05238949	A	19930917	JP 1992-334281	19921215
JP 3730667	B2	20060105		

PRIORITY APPLN. INFO.: JP 1991-347352 A1 19911227
 AB A long-lasting peptide injection composition consists of (1) a water-soluble peptide with the body clearance rate \geq 30 mL/h·kg body weight in the rat, (2) an waxlike polyethylene glycol (average mol. weight 2000-6000), and optional nontherapeutic soluble proteins, and acidic mucopolysaccharides. Thus, 10 mg pig insulin (26.8 units/mg) with the clearance rate 1416 mL/h·kg was dissolved in 5 mL 0.1 N HCl. This solution (0.7 mL) was mixed with 0.7 mL saline containing 4.2 mg polyethylene glycol (average mol. weight 2000) to give an injection composition

L3 ANSWER 31 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 1993:60783 CAPLUS
 DOCUMENT NUMBER: 118:60783
 ORIGINAL REFERENCE NO.: 118:10905a, 10908a
 TITLE: Improved high-impact, antistatic, rubber-modified styrene polymer compositions
 INVENTOR(S): Fukuoka, Mamoru; Yoneda, Ryoichi; Yanagisawa, Mitsugi; Kamikura, Masao
 PATENT ASSIGNEE(S): Dainippon Ink and Chemicals, Inc., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04168138	A	19920616	JP 1990-291921	19901031

PRIORITY APPLN. INFO.: JP 1990-291921 19901031
 AB The title compns. useful for molding into articles such as housing for elec. appliance, toys, etc. with persistent antistatic properties, are formulated from (A) copolymers derived from styrene-type monomers, unsatd. carboxylic acids, and other comonomers, (B) hydrogenated block polymers containing styrene-type blocks and conjugated diene-type blocks, (C) polyalkylene oxides or their derivs., (D) styrene polymers modified by butadiene rubbers having high degree of cis-1,4-configuration, and (E) antistatic additives. A typical title composition comprised, as A, the emulsion-polymerized styrene-methacrylic acid copolymer 20, as B, Tuftex M-1913 6, as C, a polyethylene glycol 10, as D, Dic Styrene GH-9650 74, and as E, Duspar 802D (alkylsulfonate salt antistatic agent) 2 parts.

L3 ANSWER 32 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1988:58404 CAPLUS
 DOCUMENT NUMBER: 108:58404
 ORIGINAL REFERENCE NO.: 108:9733a, 9736a
 TITLE: Toilet-cleaning compositions containing polyethylene glycols and ethylene oxide-propylene oxide copolymers
 INVENTOR(S): Kunimura, Etsuo
 PATENT ASSIGNEE(S): Takasago Perfumery Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 62197494	A	19870901	JP 1986-38166	19860225
PRIORITY APPLN. INFO.:			JP 1986-38166	19860225

AB The title compns. show minimal changes in viscosity with temperature during summer. Polyethylene glycol (mol. weight 3000-4000, solidification point 53-56°) 63, ethylene oxide-propylene oxide copolymer (Adeka Carpol GH-10) 20, polyethylene glycol (mol. weight 7000-9000, solidification point 58-63°) 8, blue dye 4, and perfume 5% were blended under heat (from 80° to 60°), added to a container at 53°, and cooled to give a waxlike cleaning composition

L3 ANSWER 33 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1985:472745 CAPLUS
 DOCUMENT NUMBER: 103:72745
 ORIGINAL REFERENCE NO.: 103:11713a, 11716a
 TITLE: Water-based ink compositions for ball point pens
 PATENT ASSIGNEE(S): Pilot Ink Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 60047082	A	19850314	JP 1983-155297	19830825
PRIORITY APPLN. INFO.:			JP 1983-155297	19830825

AB The title compns., which afford good lubrication and give good lines even in high-speed writing, contain a dye, water, and ≥1 compound R₁CO₂(CH₂CH₂O)_nR (R = H, OCR2; R₁, R₂ = C₁₁-20 alkyl, alkenyl; n = 3-24). Thus, Acid Phloxine (C.I. 45410) [18472-87-2] 2, Eosine GH (C.I. 45380) [17372-87-1] 3.5, propylene glycol 10, thiодиэтилен glycol 10, poly(vinyl alc.) 0.3, phenol 0.4, polyethylene glycol monostearate [9004-99-3] (I) 1, and water 72.8 parts were mixed to prepare a red ink, which afforded good writing lines at high speed compared with inferior properties for an ink composition without I.

L3 ANSWER 34 OF 34 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1977:541296 CAPLUS
 DOCUMENT NUMBER: 87:141296
 ORIGINAL REFERENCE NO.: 87:22283a, 22286a
 TITLE: Long-acting somatostatin composition
 INVENTOR(S): Fenichel, Richard L.; Levin, Howard J.
 PATENT ASSIGNEE(S): American Home Products Corp., USA
 SOURCE: U.S., 3 pp.

CODEN: USXXAM

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4041155	A	19770809	US 1974-518650	19741029
			US 1974-518650	19741029

PRIORITY APPLN. INFO.:

AB Growth-hormone-release-inhibiting compns.
with prolonged action containing Somatostatin [38916-34-6] (a cyclic disulfide tetradecapeptide) or a linear somatostatin (the reduced tetradecapeptide) are prepared by dissolving the drug in water, followed by adding sufficient polyethylene glycol 400 [25322-68-3] or polyethylene glycol 300 to make .apprx.80% of the composition Thus, a formulation containing 500 mg of the cyclic tetradecapeptide/mL was prepared by dissolving 500 mg of it in 0.2 mL water and adding, with stirring, 0.8 mL polyethylene glycol 400. The prolongation of the inhibition of growth hormone release by the formulation was demonstrated when it was injected s.c. into rats.

=> Log Off H

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 09:46:47 ON 14 JUL 2009